Full-Time

GRAIL Galleri Consultant

Medical Sales

Confirmed live in the last 24 hours

GRAIL

GRAIL

1,001-5,000 employees

Develops blood tests for early cancer detection

Biotechnology
Healthcare

Compensation Overview

$130k - $163kAnnually

+ Annual Bonus + Incentive Plan + Long-term Incentive Plan

Senior, Expert

Seattle, WA, USA

Candidates must reside within the territory in one of these locations: Seattle, Edmond, or Tacoma.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Sales

You match the following GRAIL's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree required
  • Minimum 8+ years of sales experience within lab, pharmaceutical, or biotechnology industry or 12+ years of overall sales experience including at least 4+ years of recent sales experience within lab, pharmaceutical, or biotechnology industry
  • Documented history of sales performance success and accolades; demonstrated strong selling skills and deep understanding of the selling process in the healthcare industry
  • New product launch experience with a complex, highly technical product - LDT or new product category launch experience is preferred; ability to translate complex science into compelling customer messages that drive action
  • Working knowledge of geography and customer base; existing relationships with concierge medicine and/or health system providers is preferred
  • Understanding of environmental and industry trends, and impact on customers
  • An accomplished track record of driving growth within an owned territory or customer base (as the single point of accountability for performance of a sales territory)
  • Ability to thrive and deliver value in a complex, cross-functional working environment; ability to build and maintain key internal relationships, drive strategic sales and marketing solutions, execute sales strategy focusing on growth, and tailor solutions to individual customer needs leveraging available resources at GRAIL
  • Willingness to “roll up your sleeves and build from scratch”; enjoy the unique challenge of creating a new category one customer at a time
  • Experience working in a startup / high growth environment; comfortable with ambiguity and change
  • Passion for GRAIL’s mission
  • Advanced business acumen and granular account acumen management skills
  • Ability to travel as required as needed - approximately 10-20% of time
Responsibilities
  • Be part of a best in class commercial organization
  • Report directly to a GRAIL District Manager
  • Prospect and target primary care practices in your territory to generate interest in Galleri and identify/onboard early adopter customers
  • Represent a diverse team of professionals to enhance our competitiveness and innovation
  • Be part of a team and collaborate with internal stakeholders to succeed in creating a new paradigm in cancer screening
  • Work with executive sales leadership, marketing, customer service, billing, and other customer-facing functions to provide “on the ground” feedback that will help shape our strategies and execution plans
  • Develop and implement a business plan to support your territory’s growth
  • Demonstrate and leverage a deep understanding of the Laboratory Developed Test (LDT) market, competitive landscape and current cancer screening options, in the effective execution of sales activities and growth
  • Meet or exceed sales goals by increasing breadth and depth of prescribing, maximize the impact of promotional budgets, and execute the national sales strategy in accordance with GRAIL standards and management expectations
  • Identify opportunities in the marketplace, share best practices, and proactively communicate successful selling strategies to peers, management, cross-functional partners, and members of the Commercial Team Manage implementation of all promotional activities to support sales and marketing strategies, in accordance with high industry standards and company policies
  • Collaborate with Medical Science Liaisons (MSLs) to educate providers on the science and studies that support MCED technology, and build relationships with Key Opinion Leaders.
Desired Qualifications
  • New product launch experience with a complex, highly technical product - LDT or new product category launch experience is preferred; ability to translate complex science into compelling customer messages that drive action
  • Working knowledge of geography and customer base; existing relationships with concierge medicine and/or health system providers is preferred

GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages, enhancing treatment success rates. The company utilizes high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning to extract actionable information for early cancer detection. GRAIL differentiates itself from competitors by conducting large-scale clinical studies to ensure the effectiveness and reliability of its tests. The primary goal is to reduce global cancer mortality by enabling early diagnosis, making the disease more treatable.

Company Size

1,001-5,000

Company Stage

Acquired

Total Funding

$1.8B

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Function Health expands GRAIL's market reach and test adoption.
  • Publication in Lancet Oncology boosts GRAIL's credibility and professional acceptance.
  • Separation from Illumina allows GRAIL to pursue aggressive growth strategies.

What critics are saying

  • Potential overdiagnosis of indolent cancers could lead to unnecessary treatments.
  • Significant net loss raises concerns about GRAIL's financial sustainability.
  • Separation from Illumina may present operational challenges and require adjustments.

What makes GRAIL unique

  • GRAIL uses high-intensity sequencing for early cancer detection, setting it apart.
  • The Galleri test screens for over 50 cancers with a single blood draw.
  • GRAIL's tests focus on detecting aggressive cancers, minimizing overdiagnosis risks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.

Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.

Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.

Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

3%
PR Newswire
Feb 21st, 2025
Grail To Present At Td Cowen 45Th Annual Health Care Conference

MENLO PARK, Calif., Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m. ET.Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured

PR Newswire
Jan 14th, 2025
Patient Reported Outcomes For Grail'S Galleri® Multi-Cancer Early Detection Blood Test Published In Lancet Oncology

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection TestingMENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection (MCED) testing.PRO assessment was conducted for eligible PATHFINDER study participants with either a cancer signal detected (CSD) or no cancer signal detected (NCSD) over a 12-month follow-up period. In the PATHFINDER study, general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the Galleri® test, and intent towards guideline-recommended screening and repeat MCED testing were assessed. Three instruments used to assess PRO included an adapted Multidimensional Impact of Cancer Risk Assessment (MICRA) for distress, uncertainty and positive experience at MCED test result disclosure, PRO Measurement Information System (PROMIS) Anxiety short-form for anxiety symptoms, the Short Form 12-Item Health Survey (SF-12v2) for health-related quality of life, and a satisfaction questionnaire."Previous studies have shown that there is a temporary increase in anxiety symptoms after cancer screening, particularly for those with a test result indicating they may have cancer," said Lincoln Nadauld, MD, lead author of the study and was vice president, chief of Precision Health & Academics at Intermountain Health during the PATHFINDER study and currently CEO at Culmination Bio, Inc

PR Newswire
Dec 18th, 2024
Grail To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT.Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com

Quartz
Dec 4th, 2024
This startup says it can screen for over 50 cancers with one simple blood draw

Function Health has partnered with cancer test startup GRAIL.

Hit Consultant
Dec 4th, 2024
Function Health And Grail Collaborate To Make Multi-Cancer Early Detection Test More Accessible

What You Should Know:– Function Health, a revolutionary health management platform empowering people to live 100 healthy years, announces a collaboration with GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, to expand the reach of innovative cancer screening to transform cancer care.– Function Health’s 400,000+ members nationwide have access to GRAIL’s Galleri test—a first-of-its-kind, clinically validated multi-cancer early detection (MCED) test that screens for multiple cancers with a simple blood draw—as an add-on to its comprehensive list of 100+ lab tests.Function Health: Revolutionizing Preventative Care with Comprehensive Lab Testing and Early Cancer DetectionFunction Health is a pioneering health platform offering access to over 100 lab tests, enabling individuals to gain comprehensive insights into their overall health—including heart health, hormones, thyroid function, nutrients, toxins, immunity, and autoimmune markers. At $499 annually, the platform provides five times more testing than the average physical, which typically assesses only 19 biomarkers. Unlike traditional methods, it eliminates hidden costs, surprise bills, and insurance complications.A Groundbreaking Approach to Early Cancer DetectionFunction Health has partnered with GRAIL to offer the Galleri test, a multi-cancer early detection tool capable of identifying over 50 types of cancers, including those for which no standard screening exists (e.g., esophageal, pancreatic, ovarian, and liver). Recommended for adults at elevated cancer risk, particularly those aged 50 and older, this test detects cancer “fingerprints” before symptoms arise, offering a critical opportunity for early intervention.Dr. Mark Hyman, Co-Founder and Chief Medical Officer of Function Health, emphasized the importance of proactive health strategies: “With cancer risks rising, education, early detection, and research are crucial in combatting harmful diseases. By integrating the Galleri test into our platform, we’re enabling members to screen for cancer as part of their annual checkups, enhancing treatment options and outcomes.”Tackling a Growing Health CrisisCancer is projected to affect over two million individuals in the U.S